Livzon receives approval for YJH-012 injection clinical trials

Livzon Pharmaceutical Group Inc. (HKEX: 1513) announced that it has received the Notice of Drug Clinical Trial Approval from the National Medical Products Administration for its YJH-012 injection. The injection, a new type of siRNA drug co-developed with Youjia (Hangzhou) Bio-medical Technology Co., Ltd., aims to treat gout by inhibiting uric acid production at the genetic level. As of the announcement date, the accumulated direct investment in research and development expenses of YJH-012 injection is about RMB25.7386 million (unaudited). According to the CDE (Center for Drug Evaluation), there are no small RNA products with the same indication on the domestic market. Livzon cautions investors about the risks associated with drug development and market competition.